Effect of olanzapine in gastric cancer patients receiving chemotherapy
- Conditions
- eoplasms.Malignant neoplasm of stomach
- Registration Number
- IRCT2015070822991N2
- Lead Sponsor
- Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
gastric cancer patients whose disease diagnosed recently and candidate for chemotherapy; patient´s informed consent for participation in the study
Exclusion criteria: history of severe psychiatric problems such as severe cognitive disorders, psychotic disorders, antipsychotic medication such as risperidone, clozapine, phenothiazine,… in 30 days before or duration of the protocol; history of severe neurologic diseases such as metastasis to the brain, convulsion, ...; mental retardation; serum creatinine level more than 2 milligram per deciliter; total serum bilirubin level more than 2 milligram per deciliter; hepatic enzymes more than three times higher than upper limit of normal range; neutrophil count less than 1500; pregnancy; uncontrolled cardiac diseases such as cardiac arrhythmias, heart failure, acute myocardial infarction in the last 6 months; uncontrolled diabetes mellitus
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of life. Timepoint: 4th and 8th week after initiation of chemotherapy. Method of measurement: with standard questionnaire of WHO- QOL- BREF.;Severity of depression and anxiety in the patient. Timepoint: 4th and 8th weeks after chemotherapy. Method of measurement: Hospital Anxiety and Depression Scale (HADS).
- Secondary Outcome Measures
Name Time Method ausea and Vomiting. Timepoint: before treatment to six days after chemotherapy. Method of measurement: Rhodes index.